<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568359</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00046786</org_study_id>
    <nct_id>NCT01568359</nct_id>
  </id_info>
  <brief_title>Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors</brief_title>
  <official_title>Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the Calcium homeostasis in adult patients with
      uncontrolled acromegaly. The measurements will be repeated 3-6 months after the treatment of
      acromegaly (surgical or medical). The control group consists of patients with nonfunctioning
      pituitary tumors who will undergo surgical removal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcitriol is the active form of vitamin D. Parathyroid hormone (PTH) is secreted by the
      parathyroid glands in the neck. Both these chemicals are responsible for keeping the levels
      of calcium and phosphorous normal and also play a role in bone health. They can be measured
      in the blood. In some disorders, PTH or calcitriol levels are elevated, which results in
      increased calcium absorption from the gut, increased calcium in the bloodstream, and
      increased calcium excretion in the urine. Increased calcium in the urine can lead to the
      development of kidney stones. Increased calcium in the bloodstream can have adverse effects
      on the heart, gut, kidneys, and bones.

      Acromegaly is a condition where a pituitary tumor secretes excessive amounts of growth
      hormone. Patients with acromegaly have been found to have a higher prevalence of kidney
      stones, urinary calcium, and serum calcium when compared to normal adults. The reason for
      this is unknown but a suggested mechanism is that growth hormone stimulates the production of
      calcitriol or PTH. If this is true, then treatment of acromegaly resulting in lower growth
      hormone levels should also result in lower blood and urine calcium levels. The investigators
      want to see if patients with acromegaly have high calcitriol, and vitamin D binding protein,
      or PTH levels and see if they change after treatment of the condition. The investigators also
      want to assess the amount of calcium in the urine, before and after treatment.

      Patients with acromegaly may have disorders of bone health. The reason for this is unknown
      but a suggested mechanism is that growth hormone affects bone remodeling. The investigators
      want to see if patients with acromegaly have abnormal bone markers, specifically PINP, CTX,
      and TRAP, and to see if they change after treatment of the condition.

      In order to see if the results are specific to patients with acromegaly, the investigators
      also want to check these levels in patients who do not have acromegaly, but have a
      &quot;nonfunctioning&quot; pituitary tumor. A nonfunctioning pituitary tumor is one that does not
      secrete excessive hormones in the bloodstream.

      The specific aims of this study are:

        1. To describe baseline calcitriol/PTH status in patients with uncontrolled acromegaly.

        2. To assess the change in calcitriol/PTH levels after treatment with acromegaly (surgical
           or medical).

        3. To evaluate the calcium and calcitriol/PTH levels in patients with acromegaly compared
           to patients with nonfunctioning pituitary adenomas.

      This is a voluntary study. Adult patients with a diagnosis of acromegaly or a clinically
      nonfunctioning pituitary tumor receiving treatment at the Emory University Pituitary center
      will be given the opportunity to enroll in the study. Those that agree to participate will
      need to give written informed consent. Approximately 3 tablespoons (44ml) of blood will be
      drawn at enrollment for testing of vitamin D status and parathyroid hormone. If patients are
      already undergoing a blood draw for standard laboratory tests, then the volume of 44ml of
      blood will be obtained at the same time in order to avoid an additional needle stick. In
      addition, a 24-hour urine collection will be obtained to assess the amount of calcium present
      in the urine. Please note that medical or surgical therapy for your pituitary condition is
      determined by your endocrinologist and/or neurosurgeon and not part of the research study.

      Within 6 months after treatment for pituitary treatment is initiated, when patients return to
      Emory University pituitary clinic for routine visit, laboratory data (vitamin D and
      parathyroid hormone) and repeat urine studies (24 hour urine collection) will be collected.

      The confidentiality will be respected in all encounters. No personal identifiers are
      disclosed in any publications. Hard copy data will be kept securely in a locked office
      building with limited access and electronic data will always be password protected with
      access available to study personnel only. If abnormal results are discovered as part of
      testing done for this study, those results will be released to the patient's primary
      physician. All patients will be undergoing standard therapy for their pituitary disorder.

      Results of this study may have important implications for future studies that are designed to
      evaluate the mechanism of how growth hormone may increase calcitriol levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calcitriol/PTH</measure>
    <time_frame>Baseline and 3-6 months after trreatment of pituitary condition</time_frame>
    <description>To describe baseline calcitriol/PTH status in patients with uncontrolled acromegaly, with subanalyses based on presence of hyperprolactinemia.
To assess the change in calcitriol/PTH levels after treatment with acromegaly, with subanalyses based on type of therapy (surgical or medical).
To evaluate the calcium and calcitriol/PTH levels in patients with acromegaly compared to patients with nonfunctioning pituitary adenomas, with subanalyses based on presence of hyperprolactinemia in either group.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>Acromegaly</condition>
  <condition>Nonfunctioning Pituitary Tumor</condition>
  <arm_group>
    <arm_group_label>Group 1 - Acromegaly, Group 2 - control</arm_group_label>
    <description>Group 1 - Acromegaly patients, Group 2 - Nonfunctioning pituitary adenoma patients (control)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples obtained from subjects.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with uncontrolled acromegaly and nonfunctioning pituitary adenomas presenting to
        the Emory University Pituitary Center for medical or surgical treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with acromegaly or a nonfunctioning pituitary who will receive
             treatment for the pituitary condition.

          -  Study subjects must agree to participate in this study and provide written consent.

          -  Site- Emory Clinic/Emory University hospital.

          -  Stage of Disease: Patients with active acromegaly that is either newly diagnosed or
             uncontrolled on current therapy (as shown by GH/IGF-1 levels). Patients with
             nonfunctioning pituitary adenoma in whom surgical intervention planned based on
             current guidelines will serve as a control group.

          -  Age: Study subjects must be over 18 years of age.

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Prior other diseases: Patients chronic renal disease stage 3 or worse (estimated GFR &gt;
             60).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Ioachimescu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asst Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wongsurawat N, Armbrecht HJ, Zenser TV, Forte LR, Davis BB. Effects of hypophysectomy and growth hormone treatment on renal hydroxylation of 25-hydroxycholecalciferol in rats. J Endocrinol. 1984 Jun;101(3):333-8.</citation>
    <PMID>6610018</PMID>
  </reference>
  <reference>
    <citation>Ajibade DV, Dhawan P, Fechner AJ, Meyer MB, Pike JW, Christakos S. Evidence for a role of prolactin in calcium homeostasis: regulation of intestinal transient receptor potential vanilloid type 6, intestinal calcium absorption, and the 25-hydroxyvitamin D(3) 1alpha hydroxylase gene by prolactin. Endocrinology. 2010 Jul;151(7):2974-84. doi: 10.1210/en.2010-0033. Epub 2010 May 12.</citation>
    <PMID>20463051</PMID>
  </reference>
  <reference>
    <citation>Charoenphandhu N, Wongdee K, Krishnamra N. Is prolactin the cardinal calciotropic maternal hormone? Trends Endocrinol Metab. 2010 Jul;21(7):395-401. doi: 10.1016/j.tem.2010.02.002. Epub 2010 Mar 20.</citation>
    <PMID>20304671</PMID>
  </reference>
  <reference>
    <citation>Lancer SR, Bowser EN, Hargis GK. The effect of growth hormone on parathyroid function in rats. Endocrinology. 1976 May;98(5):1289-93.</citation>
    <PMID>1261522</PMID>
  </reference>
  <reference>
    <citation>Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML; AACE Acromegaly Guidelines Task Force. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004 May-Jun;10(3):213-25. Erratum in: Endocr Pract. 2005 Mar-Apr;11(2):144. Endocr Pract. 2008 Sep;14(6):802-3. Cook, David M [added]; Ezzat, Shereen [added]; Katznelson, Laurence [added]; Kleinberg, David L [added]; Laws, Edward R Jr [added]; Nippoldt, Todd B [added]; Swearingen, Brooke [added]; Vance, Mary Lee [added].</citation>
    <PMID>15382339</PMID>
  </reference>
  <reference>
    <citation>Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 1993 Jun;76(6):1452-7.</citation>
    <PMID>8501150</PMID>
  </reference>
  <reference>
    <citation>Nadarajah A, Hartog M, Redfern B, Thalassinos N, Wright AD, Joplin GF, Fraser TR. Calcium metabolism in acromegaly. Br Med J. 1968 Dec 28;4(5634):797-801.</citation>
    <PMID>5702295</PMID>
  </reference>
  <reference>
    <citation>Sigurdsson G, Nunziata V, Reiner M, Nadarajah A, Joplin GF. Calcium absorption and excretion in the gut in acromegaly. Clin Endocrinol (Oxf). 1973 Jul;2(3):187-92.</citation>
    <PMID>4760543</PMID>
  </reference>
  <reference>
    <citation>Takamoto S, Tsuchiya H, Onishi T, Morimoto S, Imanaka S, Mori S, Seino Y, Uozumi T, Kumahara Y. Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J Clin Endocrinol Metab. 1985 Jul;61(1):7-11.</citation>
    <PMID>3839000</PMID>
  </reference>
  <reference>
    <citation>Halse J, Haugen HN. Calcium and phosphate metabolism in acromegaly. Acta Endocrinol (Copenh). 1980 Aug;94(4):459-67.</citation>
    <PMID>6254298</PMID>
  </reference>
  <reference>
    <citation>Hennessey JV, Jackson IM. Clinical features and differential diagnosis of pituitary tumours with emphasis on acromegaly. Baillieres Clin Endocrinol Metab. 1995 Apr;9(2):271-314. Review.</citation>
    <PMID>7625986</PMID>
  </reference>
  <reference>
    <citation>Brown DJ, Spanos E, MacIntyre I. Role of pituitary hormones in regulating renal vitamin D metabolism in man. Br Med J. 1980 Feb 2;280(6210):277-8.</citation>
    <PMID>7357340</PMID>
  </reference>
  <reference>
    <citation>White HD, Ahmad AM, Durham BH, Chandran S, Patwala A, Fraser WD, Vora JP. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab. 2006 Mar;91(3):913-9. Epub 2005 Dec 13.</citation>
    <PMID>16352693</PMID>
  </reference>
  <reference>
    <citation>Lund B, Eskildsen PC, Lund B, Norman AW, SÃ¸rensen OH. Calcium and vitamin D metabolism in acromegaly. Acta Endocrinol (Copenh). 1981 Apr;96(4):444-50.</citation>
    <PMID>7211102</PMID>
  </reference>
  <reference>
    <citation>Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab. 2003 Dec;88(12):5650-5.</citation>
    <PMID>14671148</PMID>
  </reference>
  <reference>
    <citation>Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J. Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):555-74. doi: 10.1016/j.beem.2009.05.010. Review.</citation>
    <PMID>19945023</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Adriana Ioachimescu, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

